Primary Outcome Measures
Confirmed Objective Response Rate (Breast, Cervical Cohorts) [Time Frame: From enrollment date to first confirmed Complete or Partial Response, whichever came earlier, up to 18 months] [Designated as safety issue: ]
Objective Response Rate - First Tumor Assessment (Other Cohorts) [Time Frame: From enrollment date to first Complete or Partial Response, whichever came earlier, up to 8 or 9 weeks] [Designated as safety issue: ]
Secondary Outcome Measures
Progression-Free Survival (PFS) [Time Frame: From enrollment date until the date of first documented progression, or date of death from any cause, whichever came first, assessed up to 18 months] [Designated as safety issue: ]
Confirmed Objective Response Rate (Other Cohorts) [Time Frame: From enrollment date to first confirmed Complete or Partial Response, whichever came earlier, up to 18 months] [Designated as safety issue: ]
Objective Response Rate - First Tumor Assessment (Breast, Cervical Cohorts) [Time Frame: From enrollment date to first Complete or Partial Response, whichever came earlier, up to 8 or 9 weeks] [Designated as safety issue: ]
Clinical Benefit Rate (CBR) [Time Frame: From enrollment date to first documented response or stable disease =16, or =24 weeks for breast cancer, assessed up to 18 months] [Designated as safety issue: ]
Duration of Response (DOR) [Time Frame: From first response to first disease progression or death, assessed up to 18 months] [Designated as safety issue: ]
Overall Survival (OS) [Time Frame: From enrollment date to death, assessed up to two years] [Designated as safety issue: ]
Incidence of Treatment-Emergent Adverse Events [Time Frame: From first dose through 28 days after the last dose, assessed up to 18 months] [Designated as safety issue: ]